Our recent pilot study showed better outcomes using a combination of low-dose cyclosporine and glucosamine than cyclosporine alone in the treatment of atopic dermatitis (AD). Here, a randomized, placebo-controlled, double-blind, parallel-designed study was planned to compare the efficacy and safety of low-dose cyclosporine and glucosamine combination to low-dose cyclosporine alone for the treatment of patients with moderate to severe AD. AD patients with a Severity Scoring of Atopic Dermatitis (SCORAD) index ≥ 30 were randomly assigned in a 1:1 ratio to receive either cyclosporine 2 mg/kg and glucosamine 25 mg/kg (group A) or cyclosporine and placebo (group B) for 8 weeks. SCORAD indices, serum levels of chemokine ligand 17 and interleukin-31, eosinophil counts, and blood cyclosporine levels were examined before and after treatment. The SCORAD indices for group A (n = 19) were significantly reduced after the treatment and a significant correlation between the changes in the SCORAD indices and changes in the serum levels of chemokine ligand 17, but not interleukin-31, was detected. Glucosamine combined with cyclosporine did not increase adverse events and serum cyclosporine levels compared with cyclosporine alone. Therefore, combination of low-dose cyclosporine and glucosamine may be useful to allow the long-term use of cyclosporine in the treatment of patients with moderate to severe AD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/dth.12163 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of underlying disease and total body irradiation on the incidence of graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Transplant Cell Ther
January 2025
University of Calgary, Calgary, Alberta, Canada; Alberta Health Services, Calgary, Alberta, Canada.
Background: Multiple factors have been described to influence the risk of acute or chronic graft-versus-host disease (aGVHD or cGVHD) after allogeneic hematopoietic cell transplantation (HCT), including underlying chronic myeloid leukemia (CML) and high-dose total body irradiation (TBI). However, the impact of the underlying disease or low-dose TBI on the risk of GVHD in the modern era has not been determined.
Objective: To determine risk factors for GVHD in the modern era in the setting of antithymocyte globulin (ATG)-based GVHD prophylaxis.
Involvement of necroptosıs and apoptosıs ın protectıve effects of cyclosporın a on ischemıa-reperfusıon injury in rat kıdney.
J Mol Histol
December 2024
Department of Pharmacology, School of Medicine, Uskudar University, Istanbul, Turkey.
Article Synopsis
- The study examined how low dose cyclosporin A (CsA) can protect rat kidneys from damage caused by ischemia-reperfusion (IR) injury, focusing on mechanisms of cell death.
- Three groups were tested: a control group, an IR group (exposed to restricted blood flow), and an IR + CsA group (received CsA before the IR procedure).
- Results showed that CsA significantly improved kidney function and reduced injury markers compared to the IR group, indicating its protective effects against IR-related kidney damage.
Late-onset tacrolimus-induced encephalopathy in lung transplant recipient: Case report.
Heliyon
November 2024
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Organ transplantation, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, PR China.
Article Synopsis
- * A case study of a 61-year-old woman showed confusion and muscle stiffness 29 months post-lung transplant, revealing a diagnosis of tacrolimus-induced encephalopathy despite normal drug levels in her blood.
- * After switching her treatment from tacrolimus to cyclosporine, her neurological symptoms improved, indicating that tacrolimus was the cause of her condition, even when drug levels were considered safe.
Induced pluripotent stem-cell-derived corneal epithelium for transplant surgery: a single-arm, open-label, first-in-human interventional study in Japan.
Lancet
November 2024
Department of Ophthalmology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan; Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Osaka, Japan; Premium Research Institute for Human Metaverse Medicine, Osaka University, Suita, Osaka, Japan. Electronic address:
Background: The loss of corneal epithelial stem cells from the limbus at the edge of the cornea has severe consequences for vision, with the pathological manifestations of a limbal stem-cell deficiency (LSCD) difficult to treat. Here, to the best of our knowledge, we report the world's first use of corneal epithelial cell sheets derived from human induced pluripotent stem cells (iPSCs) to treat LSCD.
Methods: This non-randomised, single-arm, clinical study involved four eyes of four patients with LSCD at the Department of Ophthalmology, Osaka University Hospital.
Comparison of a voclosporin-based triple immunosuppressive therapy to high-dose glucocorticoid-based immunosuppressive therapy: a propensity analysis of the AURA-LV and AURORA 1 studies and ALMS.
Lupus Sci Med
November 2024
Columbia University College of Physicians and Surgeons, New York, New York, USA.
Article Synopsis
- High-dose glucocorticoid (GC)-based treatments for lupus nephritis are common but can cause significant side effects and are not always fully effective; this study explored the impact of adding voclosporin to a low-dose GC regimen.* -
- Participants were matched from two study groups: those receiving voclosporin with low-dose GCs and mycophenolate mofetil (MMF), and those on high-dose GCs with MMF and intravenous cyclophosphamide (IVC); safety and efficacy were evaluated over 6 months.* -
- Results indicated that the voclosporin group experienced fewer adverse events and achieved better reductions in urine protein levels compared to those receiving high-dose GCs
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!